Novartis International AG: Data at ECTRIMS to confirm Novartis' Gilenya® long-term efficacy on reducing brain volume loss and

   Novartis International AG: Data at ECTRIMS to confirm Novartis' Gilenya®
long-term efficacy on reducing brain volume loss and real-world relapse rates
                                    in MS

Novartis International AG / Data at ECTRIMS to confirm Novartis' Gilenya®
long-term efficacy on reducing brain volume loss and real-world relapse rates
in MS . Processed and transmitted by Thomson Reuters ONE. The issuer is solely
responsible for the content of this announcement.

  *New four-year data will show continued Gilenya treatment reduced brain
    volume loss in MS patients compared to delaying treatment with Gilenya by
    two years
  *Data will strengthen the link between brain volume loss and disability
    progression, highlighting the importance of reducing brain volume loss in
    patients with MS
  *Real-world patient data will confirm superiority of Gilenya compared to
    standard therapies (interferon and glatiramer acetate) in reducing MS
    relapse rates

Basel, September  25,  2013-  New  data  showing  the  benefits  of  Gilenya^® 
(fingolimod) on patient outcomes in multiple sclerosis (MS) will be  presented 
at the 29^th Congress of the European Committee for Research and Treatment  in 
Multiple Sclerosis (ECTRIMS)  in Copenhagen,  Denmark, adding  to the  growing 
evidence base for Gilenya in both clinical trial and real-world settings.

New four-year data from  the pivotal FREEDOMS  and FREEDOMS extension  studies 
plus  a  separate  analysis  of  three  studies  (FREEDOMS,  FREEDOMS  II  and 
TRANSFORMS) will show  the benefits  of continued Gilenya  treatment on  brain 
volume loss  compared to  delayed  treatment of  two  years. These  data  will 
reinforce what we  know about the  correlation between brain  volume loss  and 
disability, underlining the need for effectively addressing brain volume  loss 
in patients with  MS. Data  from international and  U.S. real-world  databases 
will also confirm the  favorable effect of Gilenya  on reducing relapse  rates 
for patients with MS.

"It's very encouraging for patients that we continue to confirm the long  term 
benefits Gilenya  delivers  in  MS,"  said Dr.  Timothy  Wright,  Global  Head 
Development, Novartis  Pharmaceuticals. "These  new  data will  emphasize  the 
importance of reducing brain volume loss and relapse rates for patients,  with 
increasing evidence on  the effectiveness  of Gilenya from  both clinical  and 
real-world settings."

Novartis MS portfolio highlights at ECTRIMS include:

  *Six poster presentations on the importance of, and impact of Gilenya on,
    brain volume loss.
  *Ten poster presentations on the efficacy of Gilenya both in clinical
    trials and real-world settings.
  *Nine posters, three oral presentations will reinforce the tolerability and
    safety profile of Gilenya.
  *Eight poster presentations discuss the real-world evidence for Gilenya.
  *Nine poster presentations will reinforce success of Gilenya in a
    real-world setting.
  *Eleven posters highlight the breadth of Novartis' pipeline.

In addition to marketed products Gilenya and Extavia^® (interferon beta-1b for
subcutaneous injection)  the Novartis  MS portfolio  includes  investigational 
compounds BAF312 (siponimod), and AIN457 (secukinumab).

About Multiple Sclerosis
While its exact cause is unknown, multiple sclerosis (MS) is an autoimmune
disease of the central nervous system (CNS) that causes the body to turn
against itself by mistaking normal cells for foreign cells[1]. In MS the
myelin sheath, the covering that protects nerve fibers, is damaged by the
inflammation that occurs when the body's immune cells attack the nervous
system[2]. This neuro-inflammatory damage can occur in any area of the brain,
optic nerve and spinal cord and cause a range of physical and mental problems
including loss of muscle control and strength, vision, balance, sensation and
mental function[3]. Up to 2.5 million people worldwide are affected by MS[4],
most often younger people between the ages of 20 and 40[5].

About Gilenya
Gilenya is the first oral therapy approved to treat relapsing forms of MS and
the first in a new class of compounds called sphingosine 1-phosphate receptor
modulators[6]-[7]. It is thought that Gilenya works in two ways against the
destructive processes that drive MS disease progression by affecting not only
the immune system to reduce inflammatory damage but also the CNS to promote
neuroprotection and repair[7]. Gilenya is thought to act by preventing
lymphocytes (the cells that cause inflammation and damage in the CNS) from
leaving the lymphoid tissues, thus reducing their entry into the central
nervous system and potential for damage[6]-[7]. Gilenya is also able to cross
the blood-brain barrier and act on the neurodegeneration process in the brain
and spinal cord[6]-[7].

Gilenya is  the only  oral  MS treatment  that  provides early  and  long-term 
reduction in the rate of brain  volume loss and enduring high efficacy  across 
all  key  disease  activity  measures[8]-[13].  In  clinical  trials,  Gilenya 
exhibited a  well-characterized  safety  profile and  very  good  tolerability 
profile[9],[10]. The most common side  effects were headache, hepatic  enzymes 
increased, influenza, sinusitis,  diarrhea, back pain,  and cough[9],[10].  To 
date, more than 71,000 patients have been treated with Gilenya demonstrating a
positive benefit-risk profile in clinical study and real-world settings[14].

Gilenya is licensed from Mitsubishi Tanabe Pharma Corporation.

Disclaimer
The foregoing release contains forward-looking statements that can be
identified by terminology such as "to confirm," "will," "encouraging,"
"continue," "pipeline," "investigational," or similar expressions, or by
express or implied discussions regarding potential new indications or labeling
for Gilenya, potential future marketing approvals for investigational MS
therapies, or regarding potential future revenues from Gilenya or from such
investigational therapies. You should not place undue reliance on these
statements. Such forward-looking statements reflect the current views of
management regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or
implied by such statements. There can be no guarantee that Gilenya will be
submitted or approved for any additional indications or labeling in any
market, or at any particular time. Nor can there be any guarantee that other
Novartis investigational MS therapies will be submitted or approved for sale
in any country, or at any particular time. Neither can there be any guarantee
that such products will achieve any particular levels of revenue in the
future. In particular, management's expectations regarding these products
could be affected by, among other things, unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; unexpected regulatory actions or delays or government
regulation generally; competition in general; government, industry and general
public pricing pressures; unexpected manufacturing issues; the company's
ability to obtain or maintain patent or other proprietary intellectual
property protection; the impact that the foregoing factors could have on the
values attributed to the Novartis Group's assets and liabilities as recorded
in the Group's consolidated balance sheet, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those anticipated, believed, estimated or expected.
Novartis is providing the information in this press release as of this date
and does not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events
or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2012, the Group
achieved net sales of USD 56.7 billion, while R&D throughout the Group
amounted to approximately USD 9.3 billion (USD 9.1 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 131,000 full-time-equivalent associates and operate in more than
140 countries around the world. For more information, please visit
http://www.novartis.com.

Novartis   is    on    Twitter.   Sign    up    to   follow    @Novartis    at 
http://twitter.com/novartis.

References

[1]    http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/. Accessed September 2013.
[2]    http://www.mssociety.org.uk/what-is-ms/information-about-ms/about-ms. Accessed September 2013.
[3]    http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/symptoms/index.aspx.
       Accessed September 2013.
[4]    Multiple Sclerosis International Federation. Atlas of MS [online]. Available at: www.atlasofms.org.
       Accessed September 2013.
[5]    http://emsp.org/multiple-sclerosis/ms-fact-sheet. Accessed September 2013.
[6]    Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the
       central nervous system. Br J Pharmacol 2009;158(5):1173-1182.
[7]    Chun J, Hartung HP. Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis. Clin
       Neuropharmacol. 2010 March-April;33(2):91-101.
[8]    Chin PS, Calabresi PA, Zhang Y, von Rosenstiel P, Kappos L. Early effect of fingolimod on clinical
       and MRI related outcomes in relapsing multiple sclerosis. Poster presented at: 28th Congress of the
       European Committee for Treatment and Research in Multiple Sclerosis; October 10-13, 2012; Lyon,
       France. Abstract P459.
[9]    Kappos L, Radue E-W, O'Connor P, et al; for FREEDOMS Study Group. A placebo-controlled trial of oral
       fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
[10]   Cohen JA, Barkhof F,  Comi G, et al;  for TRANSFORMS Study Group.  Oral fingolimod or  intramuscular 
       interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
[11]   Cohen J, et al. Fingolimod-effect  on brain atrophy and clinical/MRI  correlations in Three Phase  3 
       studies - TRANSFORMS, FREEDOMS and FREEDOMS II. Abstract presented at AAN, San Diego, March 2013.
[12]   Montalban X, Barkhof F, Comi G, et al. Long-term comparison of fingolimod with interferon beta-1a:
       results of 4.5-year follow-up from the extension phase III TRANSFORMS study Poster presented at:
       28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October
       10-13, 2012; Lyon, France. Abstract P517.
[13]   Kappos L, Radue E-W, O'Connor P, et al. Phase 3 FREEDOMS study extension: fingolimod (FTY720)
       efficacy in patients with relapsing-remitting multiple sclerosis receiving continuous or
       placebo-fingolimod switched therapy for up to 4 years. Poster presented at: 28th Congress of the
       European Committee for Treatment and Research in Multiple Sclerosis; October 10-13, 2012: Lyon,
       France. Poster P979.
[14] Novartis data on file.

                                    # # #
                           Novartis Media Relations

Central media line: +41 61 324 2200
Eric Althoff                         Katrina Lucking
Novartis Global Media Relations      Novartis Global Pharma Communications
+41 61 324 7999 (direct)             +41 61 324 12 18 (direct)
+41 79 593 4202 (mobile)             +41 79 171 8267 (mobile)
eric.althoff@novartis.com            katrina.lucking@novartis.com

e-mail: media.relations@novartis.com

For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp@thenewsmarket.com.

Novartis Investor Relations

Central phone:         +41 61 324 7944
Samir Shah             +41 61 324 7944 North America:
Pierre-Michel Bringer  +41 61 324 1065 Stephen Rubino      +1 862 778 8301
Thomas Hungerbuehler   +41 61 324 8425 Jill Pozarek        +1 212 830 2445
Isabella Zinck         +41 61 324 7188
e-mail:                                e-mail: investor.relations@novartis.com
investor.relations@novartis.com

Media release (PDF)

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Novartis International AG via Thomson Reuters ONE
HUG#1731220

--- End of Message ---

Novartis International AG
P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;